Variants at 8q24.21 have been shown to be associated with glioma development. By means of tag SNP genotyping and imputation, pooled next-generation sequencing using long-range PCR and subsequent validation SNP genotyping, we identified seven low-frequency SNPs at 8q24.21 that were strongly associated with glioma risk (P = 1 × 10−25 to 1 × 10−14). The most strongly associated SNP, rs55705857, remained highly significant after individual adjustment for the other top six SNPs and two previously published SNPs. After stratifying by histological and tumor genetic subtype, the most significant associations of rs55705857 were with oligodendroglial tumors and gliomas with mutant IDH1 or IDH2 (odds ratio (OR) = 5.1, P = 1.1 × 10−31 and OR = 4.8, P = 6.6 × 10−22, respectively). Strong associations were observed for astrocytomas with mutated IDH1 or IDH2 (grades 2–4) (OR = 5.16–6.66, P = 4.7 × 10−12 to 2.2 × 10−8) but not for astrocytomas with wild-type IDH1 and IDH2 (smallest P = 0.26). The conserved sequence block that includes rs55705857 is consistently modeled as a microRNA.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat. Genet. 41, 899–904 (2009).

  2. 2.

    et al. Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet. 204, 13–18 (2011).

  3. 3.

    et al. Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum. Mol. Genet. 20, 2897–2904 (2011).

  4. 4.

    et al. Associations of glioma risk loci by IDH1 mutation status. Neuro-oncol. 13 (suppl. 3), iii27 (2011).

  5. 5.

    et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).

  6. 6.

    et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl. Cancer Inst. 103, 143–153 (2011).

  7. 7.

    et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75, 1560–1566 (2010).

  8. 8.

    et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors, a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 16, 1597–1604 (2010).

  9. 9.

    et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age, a study of 1,010 diffuse gliomas. Acta Neuropathol. 118, 469–474 (2009).

  10. 10.

    et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma, Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol. 24, 2707–2714 (2006).

  11. 11.

    et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J. Neurooncol. 103, 221–230 (2011).

  12. 12.

    et al. A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q. Hum. Genet. 131, 77–85 (2012).

  13. 13.

    et al. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J. Thorac. Oncol. 6, 132–138 (2011).

  14. 14.

    et al. Genome-wide association study of pancreatic cancer in Japanese population. PLoS ONE 5, e11824 (2010).

  15. 15.

    et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat. Genet. 41, 1001–1005 (2009).

  16. 16.

    & Bioinformatic resources of microRNA sequences, gene targets, and genetic variation. Front. Genet. 3, 31 (2012).

  17. 17.

    et al. 19p13.1 is a triple negative–specific breast cancer susceptibility locus. Cancer Res. 72, 1795–1803 (2012).

  18. 18.

    et al. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J. Natl. Cancer Inst. 102, 959–971 (2010).

  19. 19.

    et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet. 42, 874–879 (2010).

  20. 20.

    & The inherited genetics of ovarian and endometrial cancer. Curr. Opin. Genet. Dev. 20, 231–238 (2010).

  21. 21.

    et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat. Genet. 41, 1058–1060 (2009).

  22. 22.

    et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat. Genet. 41, 1122–1126 (2009).

  23. 23.

    et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J. Natl. Cancer Inst. 100, 962–966 (2008).

  24. 24.

    et al. Interpretation of association signals and identification of causal variants from genome-wide association studies. Am. J. Hum. Genet. 86, 730–742 (2010).

  25. 25.

    et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510–522 (2010).

  26. 26.

    et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474–478 (2012).

  27. 27.

    et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479–483 (2012).

  28. 28.

    et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat. Genet. 41, 905–908 (2009).

  29. 29.

    et al. Reproductive factors and hormone use and risk of adult gliomas. Cancer Causes Control 20, 87–96 (2009).

  30. 30.

    et al. Nonsynonymous coding single-nucleotide polymorphisms spanning the genome in relation to glioblastoma survival and age at diagnosis. Clin. Cancer Res. 13, 197–205 (2007).

  31. 31.

    et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 18, 636–645 (2000).

  32. 32.

    , , & Genotype imputation. Annu. Rev. Genomics Hum. Genet. 10, 387–406 (2009).

  33. 33.

    et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am. J. Hum. Genet. 81, 559–575 (2007).

  34. 34.

    & A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am. J. Hum. Genet. 84, 210–223 (2009).

  35. 35.

    , & RNA secondary structure prediction by centroids in a Boltzmann weighted ensemble. RNA 11, 1157–1166 (2005).

Download references


The authors wish to acknowledge study participants, the clinicians and research staff at the participating medical centers, deCODE Genetics, the late Bernd Scheithauer, the Mayo Clinic Comprehensive Cancer Center Biospecimens Accessioning and Processing Shared Resource and Genotyping Shared Resource and the UCSF Diller Cancer Center Genomics Core. Work at the Mayo Clinic was supported by the US National Institutes of Health (NIH; grants P50CA108961 and P30CA15083), the National Institute of Neurological Disorders and Stroke (grant RC1NS068222Z), the Bernie and Edith Waterman Foundation and the Ting Tsung and Wei Fong Chao Family Foundation. Work at the University of California, San Francisco, was supported by the NIH (grants R01CA52689, P50CA097257, R01CA126831 and R25CA112355), as well as the National Brain Tumor Foundation and the UCSF Lewis Chair in Brain Tumor Research, and by donations from families and friends of John Berardi, Helen Glaser, Elvera Olsen, Raymond E. Cooper and William Martinusen.

Author information

Author notes

    • Yuanyuan Xiao
    • , Hugues Sicotte
    • , Paul A Decker
    • , Thomas M Kollmeyer
    • , Helen M Hansen
    •  & Matthew L Kosel

    These authors contributed equally to this work.

    • Robert B Jenkins
    • , John K Wiencke
    • , Jeanette E Eckel-Passow
    •  & Margaret R Wrensch

    These authors jointly directed this work.


  1. Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

    • Robert B Jenkins
    • , Thomas M Kollmeyer
    • , Alissa A Caron
    • , Stephanie R Fink
    • , Chandralekha Halder
    • , Amanda L Rynearson
    • , Caterina Giannini
    •  & Daniel H Lachance
  2. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.

    • Yuanyuan Xiao
    • , Paige Bracci
    •  & Joe L Wiemels
  3. Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

    • Hugues Sicotte
    • , Paul A Decker
    • , Matthew L Kosel
    • , Brooke L Fridley
    •  & Jeanette E Eckel-Passow
  4. Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

    • Helen M Hansen
    • , Shichun Zheng
    • , Kyle M Walsh
    • , Terri Rice
    • , Lucie S McCoy
    • , Ivan Smirnov
    • , Joseph S Patoka
    • , George Hsuang
    • , Michael D Prados
    • , Susan M Chang
    • , Mitchel S Berger
    • , John K Wiencke
    •  & Margaret R Wrensch
  5. Program in Cancer Genetics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.

    • Kyle M Walsh
  6. Institute of Human Genetics, University of California, San Francisco, San Francisco, California, USA.

    • Joe L Wiemels
    • , John K Wiencke
    •  & Margaret R Wrensch
  7. Department of Pathology, University of California, San Francisco, San Francisco, California, USA.

    • Tarik Tihan
  8. Gladstone Institutes, San Francisco, California, USA.

    • Alexander R Pico
  9. Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

    • Jan C Buckner
  10. Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

    • Brian P O'Neill
    •  & Daniel H Lachance


  1. Search for Robert B Jenkins in:

  2. Search for Yuanyuan Xiao in:

  3. Search for Hugues Sicotte in:

  4. Search for Paul A Decker in:

  5. Search for Thomas M Kollmeyer in:

  6. Search for Helen M Hansen in:

  7. Search for Matthew L Kosel in:

  8. Search for Shichun Zheng in:

  9. Search for Kyle M Walsh in:

  10. Search for Terri Rice in:

  11. Search for Paige Bracci in:

  12. Search for Lucie S McCoy in:

  13. Search for Ivan Smirnov in:

  14. Search for Joseph S Patoka in:

  15. Search for George Hsuang in:

  16. Search for Joe L Wiemels in:

  17. Search for Tarik Tihan in:

  18. Search for Alexander R Pico in:

  19. Search for Michael D Prados in:

  20. Search for Susan M Chang in:

  21. Search for Mitchel S Berger in:

  22. Search for Alissa A Caron in:

  23. Search for Stephanie R Fink in:

  24. Search for Chandralekha Halder in:

  25. Search for Amanda L Rynearson in:

  26. Search for Brooke L Fridley in:

  27. Search for Jan C Buckner in:

  28. Search for Brian P O'Neill in:

  29. Search for Caterina Giannini in:

  30. Search for Daniel H Lachance in:

  31. Search for John K Wiencke in:

  32. Search for Jeanette E Eckel-Passow in:

  33. Search for Margaret R Wrensch in:


R.B.J. and D.H.L. led the study at the Mayo Clinic, and M.R.W. and J.K.W. led the study at UCSF. R.B.J., M.R.W., D.H.L., J.K.W., J.E.E.-P., Y.X., H.S., T.M.K., T.R., H.M.H. and P.B. contributed to manuscript preparation. Study coordination was the responsibility of S.R.F. and T.M.K. at the Mayo Clinic, and T.R. and L.S.M. at UCSF. Y.X., J.E.E.-P., H.S., K.M.W. and B.L.F. co-directed and conducted biostatistics and bioinformatics analyses, with additional support from P.A.D., M.L.K., I.S. and A.R.P. Laboratory work was performed by T.M.K., A.L.R., C.H., A.A.C. and S.R.F. under the direction of R.B.J. at the Mayo Clinic and by H.M.H., S.Z., J.S.P. and G.H. under the direction of J.K.W., J.L.W. and M.R.W. at UCSF. Pathology support, including pathology review, was provided by C.G. and T.T. Subject enrollment and clinical record review was performed or facilitated by M.D.P., S.M.C., M.S.B., J.C.B., B.P.O. and D.H.L.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Robert B Jenkins.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Tables 1 and 3–5 and Supplementary Figures 1–5

Excel files

  1. 1.

    Supplementary Table 2

    Stage 2 validation genotyping and glioma case-control association results for 157 candidate SNPs in the chromosome 8q24.21 (CCDC26) region

About this article

Publication history






Further reading